news Breaking News
clock

Emzor founder Stella Okoli steps down ahead of API plant launch

Stella Okoli, founder and chief executive of Emzor Pharmaceutical Industries Ltd., has stepped down as group managing director, handing day-to-day

Emzor founder Stella Okoli steps down ahead of API plant launch

Share

Stella Okoli, founder and chief executive of Emzor Pharmaceutical Industries Ltd., has stepped down as group managing director, handing day-to-day management of the Nigerian drugmaker to Uzoma Ezeoke as the company prepares to enter local production of active pharmaceutical ingredients (APIs). Ezeoke, a pharmacist who previously served as executive director for general duties, human resources, and finance, has assumed the managing director role, while Okoli remains the founder and chief executive of the company she established in 1977. The leadership change was disclosed at the 8th Nigeria Pharma Manufacturers’ Expo in Lagos, where Okoli called on the Federal Government to strengthen support for domestic pharmaceutical manufacturers and encourage more young pharmacists to pursue careers in drug production. “The government must encourage manufacturers,” she said, advocating more regular engagement between policymakers and industry operators. The transition comes as Emzor prepares to commission an API manufacturing plant in Sagamu, Ogun State, a project that could reduce the industry’s dependence on imported pharmaceutical ingredients and limit manufacturers’ exposure to foreign exchange volatility and global supply disruptions. Okoli said the company was positioning itself to become the first in sub-Saharan Africa to manufacture the active ingredients used in medicines. Nigeria’s pharmaceutical manufacturers rely heavily on imported APIs, particularly from India and China, leaving production costs vulnerable to exchange-rate movements, import constraints, and disruptions in international supply chains. Local production of these ingredients could help reduce some of those risks, although the impact will depend on the plant’s commissioning, production capacity, and ability to supply manufacturers at competitive prices. API plant faces commissioning delays Emzor’s Sagamu facility is designed to begin production with APIs used in antimalarial medicines before expanding into ingredients for HIV treatments and other essential drugs. The company’s laboratory has synthesised five antimalarial ingredients, including artemether and lumefantrine, according to information provided by Okoli. The project has cost about $23 million and is partly funded by a €13.85 million loan from the European Investment Bank. However, the facility has missed several commissioning targets. Initially scheduled to begin operations in 2024, the timeline was subsequently moved to late 2025 and then early 2026. No new commissioning date has been announced. The delays come as Nigerian pharmaceutical manufacturers contend with the cost of imported raw materials, currency movements and the financing requirements associated with expanding domestic production. In August, Emzor raised ₦26.7 billion through a five-year bond with an annual coupon of 19 percent, partly to complete the API facility. The bond, equivalent to about $20 million, was issued under the company’s N40 billion debt programme and was oversubscribed, indicating investor demand for the offer. The facility represents a strategic expansion beyond Emzor’s established business of manufacturing finished medicines. If operational, it could position the company to supply ingredients to domestic drugmakers and support efforts to build a more integrated pharmaceutical manufacturing industry in Nigeria. From retail pharmacy to manufacturing Founded in 1977 with N5,000 as a small chemist’s shop in Lagos, Emzor has grown into a pharmaceutical manufacturer with more than 140 products, including painkillers, antimalarials, antibiotics and vitamins. Okoli started the business using her father’s house as collateral before incorporating Emzor in 1984 and moving into manufacturing. Its product portfolio includes Emzor paracetamol, a widely recognised medicine brand in Nigeria. The company’s growth reflects Okoli’s transition from pharmaceutical retail into industrial production, a path she wants more young pharmacists to follow. Speaking at the expo, she said Emzor had hosted pharmacy students for industrial visits, giving them exposure to manufacturing processes and career opportunities beyond community pharmacy practice. “They come and visit, they learn, and they don’t want to go back to the university,” she said. Okoli also pointed to the advancement of employees within the company as evidence of its approach to workforce development. “We encourage everybody to work hard because some of our lowest entry-level staff are now managers,” she said.

Chinwe Michael Chinwe Michael is a Nigerian business journalist and media professional with over 4 years of experience covering companies, financial markets, banking, fintech, economic policy, financial inclusion, and corporate affairs. She currently leads the Companies & Markets desk at BusinessDay, where she drives coverage of Nigeria’s corporate and capital markets, translates complex financial data into accessible stories, and mentors younger journalists. Prior to that, she was the head of the financial inclusion/fintech desk. With a background in banking and finance and extensive experience in media and communications, Michael has developed expertise in financial journalism, economic analysis, investigative reporting and market intelligence. Her work examines how monetary policy, corporate performance, capital flows, technology, and regulatory decisions affect businesses, investors, and households. She was selected from about 3,000 applicants as one of 20 journalists for Cohort 4 of the MTN Media Innovation Programme, gaining exposure to new approaches to journalism, technology, and media innovation. Her international journalism experience and engagement with professionals across Russia, Dubai, Saudi Arabia, and others in different sectors have further broadened her understanding of global communication and development. Advertisement Share

You Might Also Like Coronation Infrastructure Fund deploys N2.73bn to power, transport projects FirstHoldCo appoints former Afreximbank trade finance chief to board 86% of African firms report revenue growth, but earnings outlook lags global peers Advertisement

Read the full article at BusinessDay Nigeria

Article details
Published
October 22, 2026
Last updated
November 17, 2026
Written by
ADM Staff
Reading time
5 min read
Views
14
A
Written by

ADM Staff

Platform administrator at Afridev Monitor. Oversees the newsroom platform, user access and publishing settings, keeping the site reliable and editorially consistent. Afridev Monitor tracks development, policy and business news across Africa.

Leave a Reply

Cancel Reply

Your email address will not be published.

Please Accept Cookies for Better Performance